Edwards Lifesciences Future Growth
Future criteria checks 2/6
Edwards Lifesciences is forecast to grow earnings and revenue by 3.3% and 4.8% per annum respectively. EPS is expected to grow by 4.2% per annum. Return on equity is forecast to be 23% in 3 years.
Key information
3.3%
Earnings growth rate
4.2%
EPS growth rate
| Medical Equipment earnings growth | 17.0% |
| Revenue growth rate | 4.8% |
| Future return on equity | 23.0% |
| Analyst coverage | Good |
| Last updated | 18 Dec 2024 |
Recent future growth updates
Recent updates
Is Edwards Lifesciences (NYSE:EW) A Risky Investment?
Dec 09
At US$71.27, Is Edwards Lifesciences Corporation (NYSE:EW) Worth Looking At Closely?
Nov 26Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Nov 11Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts
Oct 25Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates
Sep 11Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
Aug 30Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Aug 17Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
Jul 26Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Jul 26Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E
Jul 12Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jun 24Edwards Lifesciences Corp Looks Bullish (Technical Analysis)
Jun 22Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
May 13Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Apr 15Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear
Apr 01Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture
Feb 21Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47
Feb 08Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing
Jan 14Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Jan 09Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Dec 31Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
Oct 26Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Aug 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 6,468 | 1,588 | 1,518 | 1,748 | 30 |
| 12/31/2025 | 5,856 | 1,413 | 1,481 | 1,814 | 33 |
| 12/31/2024 | 5,909 | 1,382 | 1,160 | 1,834 | 22 |
| 9/30/2024 | 6,315 | 1,567 | 490 | 806 | N/A |
| 6/30/2024 | 6,204 | 1,540 | 552 | 866 | N/A |
| 3/31/2024 | 6,114 | 1,428 | 251 | 528 | N/A |
| 12/31/2023 | 6,005 | 1,402 | 630 | 896 | N/A |
| 9/30/2023 | 5,092 | 1,288 | 775 | 1,042 | N/A |
| 6/30/2023 | 5,168 | 1,296 | 669 | 940 | N/A |
| 3/31/2023 | 5,279 | 1,451 | 972 | 1,239 | N/A |
| 12/31/2022 | 5,382 | 1,522 | 953 | 1,218 | N/A |
| 9/30/2022 | 5,364 | 1,459 | 1,040 | 1,309 | N/A |
| 6/30/2022 | 5,355 | 1,455 | 1,261 | 1,531 | N/A |
| 3/31/2022 | 5,357 | 1,539 | 1,428 | 1,725 | N/A |
| 12/31/2021 | 5,233 | 1,503 | 1,402 | 1,732 | N/A |
| 9/30/2021 | 5,095 | 1,477 | 1,409 | 1,758 | N/A |
| 6/30/2021 | 4,925 | 1,462 | 1,050 | 1,443 | N/A |
| 3/31/2021 | 4,474 | 851 | 717 | 1,148 | N/A |
| 12/31/2020 | 4,386 | 823 | 647 | 1,054 | N/A |
| 9/30/2020 | 4,369 | 794 | 692 | 1,057 | N/A |
| 6/30/2020 | 4,322 | 744 | 941 | 1,279 | N/A |
| 3/31/2020 | 4,484 | 1,108 | 1,087 | 1,389 | N/A |
| 12/31/2019 | 4,348 | 1,047 | 905 | 1,183 | N/A |
| 9/30/2019 | 4,152 | 774 | 809 | 1,073 | N/A |
| 6/30/2019 | 3,964 | 725 | 705 | 978 | N/A |
| 3/31/2019 | 3,821 | 765 | 523 | 777 | N/A |
| 12/31/2018 | 3,723 | 722 | 685 | 927 | N/A |
| 9/30/2018 | 3,634 | 712 | 754 | 998 | N/A |
| 6/30/2018 | 3,549 | 657 | N/A | 966 | N/A |
| 3/31/2018 | 3,447 | 560 | N/A | 1,024 | N/A |
| 12/31/2017 | 3,435 | 584 | N/A | 1,001 | N/A |
| 9/30/2017 | 3,315 | 745 | N/A | 838 | N/A |
| 6/30/2017 | 3,232 | 716 | N/A | 733 | N/A |
| 3/31/2017 | 3,150 | 657 | N/A | 726 | N/A |
| 12/31/2016 | 2,964 | 570 | N/A | 704 | N/A |
| 9/30/2016 | 2,867 | 552 | N/A | 607 | N/A |
| 6/30/2016 | 2,743 | 528 | N/A | 604 | N/A |
| 3/31/2016 | 2,601 | 515 | N/A | 584 | N/A |
| 12/31/2015 | 2,494 | 495 | N/A | 550 | N/A |
| 9/30/2015 | 2,441 | 463 | N/A | 539 | N/A |
| 6/30/2015 | 2,433 | 440 | N/A | 349 | N/A |
| 3/31/2015 | 2,391 | 874 | N/A | 957 | N/A |
| 12/31/2014 | 2,323 | 811 | N/A | 1,022 | N/A |
| 9/30/2014 | 2,241 | 777 | N/A | 1,040 | N/A |
| 6/30/2014 | 2,129 | 759 | N/A | 1,160 | N/A |
| 3/31/2014 | 2,071 | 306 | N/A | 511 | N/A |
| 12/31/2013 | 2,046 | 389 | N/A | 473 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EW's forecast earnings growth (3.3% per year) is above the savings rate (2.6%).
Earnings vs Market: EW's earnings (3.3% per year) are forecast to grow slower than the US market (15.2% per year).
High Growth Earnings: EW's earnings are forecast to grow, but not significantly.
Revenue vs Market: EW's revenue (4.8% per year) is forecast to grow slower than the US market (9.1% per year).
High Growth Revenue: EW's revenue (4.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EW's Return on Equity is forecast to be high in 3 years time (23%)
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 05:15 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Edwards Lifesciences Corporation is covered by 74 analysts. 33 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Francis Mainwaring | Atlantic Equities LLP |
| David Rescott | Baird |
| Ishan Majumdar | Baptista Research |